Phytopharm plc: Interim Management Statement 1Q 2010.

Phytopharm plc has issued its Interim Management Statement (IMS) which relates to the period from 1 Oct 2009 to 11 Feb 2010 and contains information up to the date of publication of this IMS. Highlights for the period are as follows. Phytopharm announced headline results from the successful completion of two key studies in Oct 2009: a non-clinical efficacy study in the gold-standard, non-clinical model of Parkinson's disease. The oral administration of Cogane over 18 weeks significantly reduced parkinsonian disability by 43% in non-human primates, which will be clinically significant if repeated in Parkinson's disease patients. A statistically significant reduction in parkinsonian …